05/27/2026 | Press release | Distributed by Public on 05/27/2026 08:36
Multi-center and pre-clinical studies demonstrate high stone clearance and aspiration efficiency of the CVAC System compared to suction sheaths and direct-in-scope suction (DISS)
Large retrospective study of 789 patients confirms real-world CVAC System efficacy and safety are consistent with controlled trial results
PLEASANTON, CA — May 27, 2026 — Calyxo, Inc., a medical device company redefining kidney stone treatment, today highlighted the results from multiple studies presented at the American Urological Association (AUA) 2026 Annual Meeting evaluating the performance of the CVAC System across comparative analyses, benchtop testing, and real-world safety outcomes. Collectively, the data demonstrate consistent stone clearance, high aspiration efficiency, and safety outcomes across a broad range of case complexity and clinical settings.
Across the presentations, investigators reported faster stone removal1,2, reliable safety in the real world3, high stone clearance1,3, and advantages associated with reducing post-operative unplanned events.4
Several analyses also evaluated how the CVAC System’s integrated irrigation and aspiration design contributed to consistent and faster fragment clearance compared to suction sheaths and direct-in-scope suction (DISS).
“We’re seeing a high degree of consistency across clinical studies, practicing physicians, and practice settings,” said Jacqueline Welch, MD, PhD, Vice President, Medical and Clinical Affairs at Calyxo. “We now have evidence from a large number of real-world procedures demonstrating that the CVAC System delivers efficient stone clearance for a broad range of stone burdens. For patients, more complete stone clearance has important implications beyond the procedure itself, particularly in reducing downstream stone-related events.”
Jackson Cabo, MD, Endourology Fellow, Mayo Clinic, Arizona presented results from this retrospective multicenter analysis conducted by the EDGE Consortium, which evaluated the efficacy, procedural efficiency, and safety of the CVAC System compared to suction sheaths in 493 patients. Results show that:
In this in vitro controlled bench study, Brett Johnson, MD, Associate Professor, Department of Urology, UT Southwestern Medical Center, evaluated aspiration efficiency and clearance dynamics of the CVAC System and DISS using stone fragments ranging in size from 20 µm to 3.3 mm under fixed irrigation and suction. Results show that:
Study investigator Roger Sur, MD, Professor of Urology and Director, Comprehensive Kidney Stone Center, UC San Diego Health, presented results from this retrospective, multicenter analysis of 789 patients treated with the CVAC System. Among these patients, the median baseline stone burden was 14 mm, and the median baseline stone volume was 486 mm3. Results show:
“Demonstrating a strong safety profile across nearly 800 patients with high stone clearance in those patients with follow-up imaging is an important real-world finding,” noted Dr. Sur. “The REASON study adds to the established evidence supporting the safety and consistency of the CVAC System across a broad patient population.”
According to the American Urological Association, approximately 10% of people in the U.S. will have a kidney stone at some point in their lives. Kidney stone disease is a painful condition that can result in significant healthcare costs (Current Urology Reports estimates $4.1 billion in annual direct treatment costs by 2030).
The CVAC System was FDA-cleared in 2024 and enables a minimally invasive approach for kidney stone clearance. It is an all-in-one solution designed to efficiently and effectively remove kidney stones. It uses irrigation and vacuum aspiration to continuously clear stone fragments during and after laser lithotripsy, enabling physicians to achieve a stone-free outcome.
Calyxo, Inc. is an innovation-driven medical device company focused on improving care for patients with kidney stones by delivering paradigm-shifting solutions that enable urologists to safely, effectively and efficiently achieve unrivaled clinical outcomes. Learn more at calyxoinc.com.
“CVAC” and “Calyxo” are registered trademarks of Calyxo, Inc.
Media Contact:[email protected]
MAC00343.A